William Pickering
Stock Analyst at Bernstein
(2.93)
# 2,640
Out of 4,453 analysts
216
Total ratings
53.6%
Success rate
2.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by William Pickering
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals | Rated: Hold | $35 → $46 | $79.27 | -41.97% | 9 | May 13, 2026 | |
| NTLA Intellia Therapeutics | Rated: Hold | $13 → $17 | $16.03 | +6.05% | 14 | May 13, 2026 | |
| CRSP CRISPR Therapeutics AG | Rated: Hold | $50 → $56 | $53.98 | +3.74% | 9 | May 13, 2026 | |
| BEAM Beam Therapeutics | Rated: Buy | $40 → $39 | $33.93 | +14.94% | 18 | May 13, 2026 | |
| DYN Dyne Therapeutics | Rated: Hold | $23 → $24 | $20.61 | +16.45% | 7 | May 13, 2026 | |
| BBIO BridgeBio Pharma | Reiterated: Buy | $100 → $114 | $69.69 | +63.58% | 4 | May 8, 2026 | |
| BMRN BioMarin Pharmaceutical | Rated: Buy | $94 → $82 | $57.35 | +42.98% | 21 | May 5, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Buy | $577 → $572 | $480.18 | +19.12% | 30 | May 5, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $451 → $447 | $293.17 | +52.47% | 20 | May 1, 2026 | |
| ALLO Allogene Therapeutics | Maintained: Hold | $3.85 | $2.06 | +86.89% | 8 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $916 → $921 | $620.14 | +48.51% | 25 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $20 | $16.02 | +24.84% | 5 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $28 | $38.20 | -26.70% | 1 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $35 | $34.02 | +2.88% | 1 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $157 → $201 | $201.96 | -0.48% | 10 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $65 → $89 | $78.34 | +13.61% | 22 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $34 → $9 | $15.34 | -41.33% | 12 | Nov 6, 2025 |
Arrowhead Pharmaceuticals
May 13, 2026
Rated: Hold
Price Target: $35 → $46
Current: $79.27
Upside: -41.97%
Intellia Therapeutics
May 13, 2026
Rated: Hold
Price Target: $13 → $17
Current: $16.03
Upside: +6.05%
CRISPR Therapeutics AG
May 13, 2026
Rated: Hold
Price Target: $50 → $56
Current: $53.98
Upside: +3.74%
Beam Therapeutics
May 13, 2026
Rated: Buy
Price Target: $40 → $39
Current: $33.93
Upside: +14.94%
Dyne Therapeutics
May 13, 2026
Rated: Hold
Price Target: $23 → $24
Current: $20.61
Upside: +16.45%
BridgeBio Pharma
May 8, 2026
Reiterated: Buy
Price Target: $100 → $114
Current: $69.69
Upside: +63.58%
BioMarin Pharmaceutical
May 5, 2026
Rated: Buy
Price Target: $94 → $82
Current: $57.35
Upside: +42.98%
Vertex Pharmaceuticals
May 5, 2026
Maintained: Buy
Price Target: $577 → $572
Current: $480.18
Upside: +19.12%
Alnylam Pharmaceuticals
May 1, 2026
Reiterated: Buy
Price Target: $451 → $447
Current: $293.17
Upside: +52.47%
Allogene Therapeutics
Apr 14, 2026
Maintained: Hold
Price Target: $3.85
Current: $2.06
Upside: +86.89%
Apr 8, 2026
Maintained: Buy
Price Target: $916 → $921
Current: $620.14
Upside: +48.51%
Mar 25, 2026
Maintained: Hold
Price Target: $20
Current: $16.02
Upside: +24.84%
Mar 20, 2026
Initiated Coverage: Hold
Price Target: $28
Current: $38.20
Upside: -26.70%
Mar 20, 2026
Initiated Coverage: Buy
Price Target: $35
Current: $34.02
Upside: +2.88%
Feb 6, 2026
Maintained: Hold
Price Target: $157 → $201
Current: $201.96
Upside: -0.48%
Jan 13, 2026
Maintained: Hold
Price Target: $65 → $89
Current: $78.34
Upside: +13.61%
Nov 6, 2025
Downgraded: Hold
Price Target: $34 → $9
Current: $15.34
Upside: -41.33%